EZH2 Is Overexpressed in <i>BRCA1</i> -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Julian Puppe(Oncode Institute), Jos Jonkers(The Netherlands Cancer Institute), Marieke van de Ven(The Netherlands Cancer Institute), Mark Opdam(The Netherlands Cancer Institute), Katarzyna Jóźwiak(The Netherlands Cancer Institute), Tesa Severson(The Netherlands Cancer Institute), Birgid Schömig‐Markiefka(University of Cologne), Luka Ozretić(University Hospital Cologne), Gaurav Kumar Pandey(Netherlands Heart Institute), Jelle Wesseling(Leiden University Medical Center), Chiara Svetlana Brambillasca(Netherlands Heart Institute), Wolfram Malter(University of Cologne), René Bernards(The Netherlands Cancer Institute), Hans Christian Reinhardt(German Cancer Research Center), Olaf van Tellingen(Dutch Cancer Society), Fabinshy Thangarajah(University Hospital Cologne), Philip C. Schouten(Cambridge University Hospitals NHS Foundation Trust), Michael Hauptmann(Medizinische Hochschule Brandenburg Theodor Fontane), Peter Bouwman(Schaeffler (Germany)), Maarten van Lohuizen(Oncode Institute), Sabine C. Linn(Oncode Institute), Eric Hahnen(University Hospital Cologne), Christian Eichler(University Hospital Cologne), Esther H. Lips(Oncode Institute), Carlos Caldas(University of Cambridge), Kerstin Rhiem, Peter Mallmann(University of Cologne), Rita K. Schmutzler(The University of Melbourne), Reinhard Büttner(University Hospital Cologne)
Cited by 46
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k